Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer
| Status: | Terminated |
|---|---|
| Conditions: | Cancer, Cancer, Cancer, Cancer, Other Indications |
| Therapuetic Areas: | Oncology, Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/8/2018 |
| Start Date: | September 2012 |
| End Date: | March 2014 |
Exploration of the Neuromuscular Mechanisms Associated With Sunitinib Related Fatigue
The purpose of this research study is to determine how sunitinib (sunitinib malate) causes
fatigue. Patients will be asked to complete a brief questionnaire (survey) to rate their
levels of fatigue every two weeks while they are participating in this research study. The
questionnaire takes approximately 10-15 minutes to complete and is 9 questions. A series of
physical measurements for fatigue will be performed before the first dose of sunitinib and
again (4) weeks later to see if there are any changes in physical level of fatigues
fatigue. Patients will be asked to complete a brief questionnaire (survey) to rate their
levels of fatigue every two weeks while they are participating in this research study. The
questionnaire takes approximately 10-15 minutes to complete and is 9 questions. A series of
physical measurements for fatigue will be performed before the first dose of sunitinib and
again (4) weeks later to see if there are any changes in physical level of fatigues
PRIMARY OBJECTIVES:
I. To determine the mechanisms associated with sunitinib related fatigue by recording EMG
signals during a submaximal elbow contraction, twitch force and TMS prior to and at the end
of 4 weeks of sunitinib in metastatic RCC patients.
OUTLINE:
Patients receive sunitinib malate orally (PO) daily for 4 weeks. Patients undergo
neuromuscular testing at baseline and on day 28 and complete fatigue assessment at baseline
and on days 14 and 28.
I. To determine the mechanisms associated with sunitinib related fatigue by recording EMG
signals during a submaximal elbow contraction, twitch force and TMS prior to and at the end
of 4 weeks of sunitinib in metastatic RCC patients.
OUTLINE:
Patients receive sunitinib malate orally (PO) daily for 4 weeks. Patients undergo
neuromuscular testing at baseline and on day 28 and complete fatigue assessment at baseline
and on days 14 and 28.
Inclusion Criteria:
- Histologically proven renal cell cancer with metastases; pathology from either primary
or metastatic tumor; no histologic subtype restriction
- Evidence of measurable disease according to Response Evaluation Criteria in Solid
Tumors (RECIST) criteria version 1.1 or evaluable disease
- Eastern Cooperative Oncology Group (ECOG) performance score 0 to 1
- Hemoglobin >= 9 gram/dL
- Common Terminology Criteria for Adverse Events (CTCAE) fatigue levels pre-treatment <
2
- Signed and dated informed consent
Exclusion Criteria:
- Greater than 2 previous systemic treatments for RCC
- Heart failure, New York Heart Association (NYHA) class 3 and 4
- Unstable angina (defined as ongoing use of nitrates or cardiac ischemia in the prior 6
months)
- Arrhythmia uncontrolled by medication
- Hypertension (> 160/90 mmHg) not controlled with medical management
- Brain metastases or previous cranial radiation, leptomeningeal cancer
- Surgery within 2 weeks of study entrance
- History of stroke, myasthenia gravis, multiple sclerosis, polyneuropathy
- Pregnancy or breast feeding
- Central-nervous system active medications, intake or withdrawal of which lowers
seizure threshold (determination made in consultation with study's responsible
treating physician)
- Any history of epilepsy, convulsion or seizure
- Medication-resistant epilepsy in a first-degree relative
- Cochlear implants or internal pulse generators or cardiac pacemakers or intracardiac
lines
- Metallic implants in the vicinity of discharging coil in the head or cervical spine
- Unexplained fainting spells/syncope or multiple concussions
- History of severe head trauma (followed by loss of consciousness)
- Implanted brain or spinal cord electrodes/stimulation
- Medication infusion device
- Frequent/severe headaches or severe migraines
- Past or current medical history of diagnosed or undiagnosed tinnitus
We found this trial at
1
site
Click here to add this to my saved trials
